At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 10, 2026 at 07:00 ET
Ocugen granted Celairis exclusive rights to commercialize OCU400, its investigational gene therapy for retinitis pigmentosa, in Australia, New Zealand, and ASEAN markets. Ocugen receives an upfront fee and potential milestone payments totaling up to $7.1 million, plus royalties and profit share. The deal expands global access for OCU400 ahead of Phase 3 topline data expected in Q1 2027.
- Exclusive license agreement for OCU400 in Australia, New Zealand, and ASEAN markets
- Upfront license fee plus potential development and milestone payments totaling up to $7.1 million, including $6.1 million tied to upfront and OCU400 top-line results
- High single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales in the territory
- Celairis responsible for regional regulatory submissions, market access, and commercialization
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access